Akademik Veri Yönetim Sistemi
SN Comprehensive Clinical Medicine, cilt.7, sa.1, 2025 (Scopus)
Background: Karbalex, with its carbamazepine as an active ingredient, is used to treat various types of epilepsy. Despite being uncommon, the present case highlights how crucial it is to take oral lichenoid reactions into account, particularly in patients who use Karbalex, when making a differential diagnosis of oral mucosal lesions. Case Presentation: The rare case of a 20-year-old man with a history of generalised epilepsy is described in this article. He sought consultation because of pain from mouth sores and a burning sensation when consuming cold, hot, and spicy meals, among other symptoms. For the previous five months, the patient was taking Karbalex Retard 600 mg. The diagnosis of bilateral symmetrical oral lichenoid reaction caused by Karbalex Retard 600 mg was confirmed by clinical and histological analysis. The patient was treated by stopping Karbalex Retard 600 mg and beginning with Tegretol 400 mg. The patient noticed that his mouth was starting to recover 2 months after stopping Karbalex Retard. After an additional month, all the symptoms of oral lichenoid reactions disappeared totally, which confirmed the diagnosis. Conclusion: This is an unusual case of a bilateral symmetrical oral lichenoid reaction caused by Karbalex Retard (Carbamazepine) 600 in an epileptic patient. Despite being uncommon, this case report is worth highlighting because, by removing the differential diagnosis and offering an early diagnosis, it may prevent vulnerable individuals from displaying severe symptoms.